Bristol-Myers Squibb has decided to gamble on the FDA approving Karuna Therapeutics’ schizophrenia drug candidate KarXT next year, agreeing to buy the company for approximately $14 billion.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback